logo-loader

Outlook Therapeutics over 50% enrolled in clinical study to treat wet AMD

Published: 14:52 12 Jan 2019 EST

Outlook Therapeutics (NASDAQ:OTLK) CEO Larry Kenyon sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics reaches another milestone with FDA acceptance of wet...

Outlook Therapeutics Inc (NASDAQ:OTLK) President and CEO Russ Trenary tells Proactive's Stephen Gunnion that the company faces the most significant milestone in its history if the US Food and Drug Administration (FDA) approves its investigational ophthalmic formulation for treating wet...

on 11/03/2022